Literature DB >> 7565631

Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.

H D Beall1, A M Murphy, D Siegel, R H Hargreaves, J Butler, D Ross.   

Abstract

Bioreductive antitumor quinones require reductive metabolism to produce their cytotoxic effects. A series of these compounds was screened for relative rates of reduction by the two-electron reductase, NAD(P)H:quinone oxidoreductase (DTD). The antitumor quinones streptonigrin (SN), 2,5-diaziridinyl-3-phenyl-1,4-benzoquinone (PDZQ), 2,5-diaziridinyl-3,6-dimethyl-1,4-benzoquinine (MeDZQ), and [3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)-propen ol] (EO9) were all excellent substrates for recombinant rat and human DTD. All four compounds were reduced by DTD at least 100 times faster than the clinically important bioreductive alkylating agent, mitomycin C (MC). Reduction of the antitumor quinones was generally 4-5 times more efficient by rat DTD than by human DTD. The exception was EO9, which, surprisingly, was reduced 23 times faster by rat DTD than by human DTD. The rate of reduction of each individual quinone was similar under either aerobic or anaerobic conditions, suggesting that DTD may be an important activating enzyme in the hypoxic fraction of solid tumors. The cytotoxicity of MeDZQ and MC was examined in a panel of human breast and lung cancer cell lines. The data showed good correlations between DTD activity and toxicity for both MeDZQ (r = 0.57, p = 0.054) and MC (r = 0.69, p = 0.020), confirming biochemical data that both compounds are bioactivated by DTD. In addition, IC50 values were in general lower for MeDZQ than for MC in cell lines containing elevated DTD, a finding that was consistent with metabolic data that indicated that MeDZQ was a better substrate for DTD than MC. SR, defined as the ratio of the IC50 value for the H596 NSCLC cell line (undetectable DTD activity) to the IC50 value for the H460 NSCLC cell line (high DTD activity), were determined for all five antitumor quinones. SN was the most selective (SR = 86) followed by EO9 (SR = 62), MeDZQ (SR = 17), and MC (SR = 11). Surprisingly, PDZQ, an excellent substrate for DTD, was toxic to both cell lines (SR = 1.8). These data suggest that antitumor quionones that are substrates for DTD may be selectively toxic to tumors with high DTD activity and may be useful in the treatment of those tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7565631

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  22 in total

1.  Synthesis, metabolism and in vitro cytotoxicity studies on novel lavendamycin antitumor agents.

Authors:  Wen Cai; Mary Hassani; Rajesh Karki; Ervin D Walter; Katherine H Koelsch; Hassan Seradj; Jayana P Lineswala; Hamid Mirzaei; Jeremy S York; Fatemeh Olang; Minoo Sedighi; Jennifer S Lucas; Thomas J Eads; Anthony S Rose; Sahba Charkhzarrin; Nicholas G Hermann; Howard D Beall; Mohammad Behforouz
Journal:  Bioorg Med Chem       Date:  2010-01-25       Impact factor: 3.641

2.  Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9.

Authors:  P M Loadman; M C Bibby; R M Phillips
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

3.  Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase)

Authors:  Q Zhao; X L Yang; W D Holtzclaw; P Talalay
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

4.  Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.

Authors:  D L Gustafson; H D Beall; E M Bolton; D Ross; C A Waldren
Journal:  Mol Pharmacol       Date:  1996-10       Impact factor: 4.436

5.  Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours.

Authors:  D Hussein; S V Holt; K E Brookes; T Klymenko; J K Adamski; A Hogg; E J Estlin; T Ward; C Dive; G W J Makin
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

6.  A fluopol-ABPP HTS assay to identify PAD inhibitors.

Authors:  Bryan Knuckley; Justin E Jones; Daniel A Bachovchin; Jessica Slack; Corey P Causey; Steven J Brown; Hugh Rosen; Benjamin F Cravatt; Paul R Thompson
Journal:  Chem Commun (Camb)       Date:  2010-08-25       Impact factor: 6.222

7.  Human NAD(P)H:quinone oxidoreductase type I (hNQO1) activation of quinone propionic acid trigger groups.

Authors:  Maria F Mendoza; Nicole M Hollabaugh; Suraj U Hettiarachchi; Robin L McCarley
Journal:  Biochemistry       Date:  2012-09-28       Impact factor: 3.162

8.  Profluorogenic reductase substrate for rapid, selective, and sensitive visualization and detection of human cancer cells that overexpress NQO1.

Authors:  William C Silvers; Bijeta Prasai; David H Burk; Matthew L Brown; Robin L McCarley
Journal:  J Am Chem Soc       Date:  2012-12-27       Impact factor: 15.419

9.  Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.

Authors:  Eugene Manley; David J Waxman
Journal:  J Pharmacol Exp Ther       Date:  2012-11-28       Impact factor: 4.030

10.  Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release.

Authors:  M Faig; M A Bianchet; P Talalay; S Chen; S Winski; D Ross; L M Amzel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.